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ANALYSIS OF FREE DRUG FRACTIONS USING NEAR-INFRARED
FLUORESCENT LABELS AND AN ULTRAFAST
IMMUNOEXTRACTION/DISPLACEMENT ASSAY
Corey M. Ohnmacht, John E. Schiel, and David S. Hage*
Department of Chemistry University of Nebraska Lincoln, Nebraska 68588−0304
Abstract
A chromatographic method was developed for measuring free drug fractions based on the use of an
ultrafast immunoextraction/displacement assay (UFIDA) with near-infrared (NIR) fluorescent
labels. This approach was evaluated by using it to determine the free fraction of phenytoin in serum
or samples containing the binding protein human serum albumin (HSA). Items considered in the
design of this method included the dissociation rate of HSA-bound phenytoin, the rate of capture of
free phenytoin by immunoextraction microcolumns, the behavior of NIR fluorescent labels in a
displacement format, and the overall response and stability of the resulting assay. In the final UFIDA
method, the free fraction of phenytoin was extracted in approximately 100 ms by a microcolumn
containing a small layer of anti-phenytoin antibodies. This gave a displacement peak for a NIR-
fluorescent labeled analog of phenytoin that appeared within 2−3 min of sample injection, creating
a signal proportional to the amount of free phenytoin in the sample. The UFIDA method provided
results within 1−5% of those determined by ultrafiltration for reference samples. The lower limit of
detection was 570 pM and the linear range extended up to 10 μM. This approach is not limited to
phenytoin but can be adapted for other analytes through the use of appropriate antibodies and labeled
analogs.
INTRODUCTION
Many drugs exist in two forms in the circulation: a free fraction and a fraction which is
reversibly bound to serum proteins or other agents in blood [1,2]. The free fraction of a drug
is generally thought to represent its active form, since this is the form that can cross cell
membranes or bind to receptors [3]. The binding of drugs to blood or serum components is
important in drug delivery [4]. However, the extent of this binding can be affected by various
factors which can lead to individual variations in free drug fractions [5]. For instance, the extent
of a drug's binding with serum proteins can vary as a result of illness, trauma, surgery or age
[2]. This can make it difficult to correlate the total concentration of a drug with its free fraction
and has created a need for new methods that can routinely measure free drug fractions.
Phenytoin is an anti-epileptic drug that has significant binding in blood [6,7]. This drug is
mainly bound in blood to the protein human serum albumin (HSA), with approximately 90%
of phenytoin being complexed at therapeutic levels in adults [8-14]. Two clinical situations in
which the bound fraction of phenytoin might decrease include infants with jaundice (due to
the competition of bilirubin with phenytoin for HSA) and patients that have low HSA levels
following trauma or surgery [9]. It is also possible for a patient to have an increased bound
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fraction of phenytoin, as can occur in individuals with high HSA concentrations (i.e.,
hyperalbuminemia) [9].
There have been numerous methods developed for the measurement of phenytoin's free fraction
in blood, plasma or serum [6,10,12,15-22]. Examples include techniques based on equilibrium
dialysis, ultrafiltration, and restricted access media (RAM) columns [6,10,14,15,18,19,21].
Other techniques such as CE can also be used to examine drug-protein interactions in standard
solutions [23-26], but many of these methods are not applicable for work with the small free
fractions of drugs or the complex matrices that are found in clinical samples. Some previous
methods for free phenytoin measurements suffer from long analysis times (e.g., equilibrium
dialysis) or non-specific adsorption to membranes (e.g., ultrafiltration) [19]. Other techniques
(e.g., RAM) give only an incomplete separation of phenytoin's free and bound forms, making
these methods difficult to use with real clinical samples [1,2,16,27].
This paper describes an alternative chromatographic-based approach for measuring free drug
fractions based on an ultrafast immunoextraction/displacement assay (UFIDA), as illustrated
in Figure 1 [28]. This approach uses an immunoextraction microcolumn that can bind a
measurable amount of the free analyte (e.g., phenytoin) on a time scale that is sufficiently small
to avoid dissociation of this analyte from its binding agents in the sample (e.g., HSA). At the
beginning of this assay, shown in the upper left of Figure 1(a), an excess of a labeled analog
of the analyte is injected onto the immunoextraction microcolumn in the presence of an
application buffer. Some of this labeled analog will bind to antibodies in the column while the
remainder will be washed away prior to sample injection. When a sample is later passed through
the column, the free fraction of the analyte will compete with any labeled analog that is
momentarily dissociated from the immobilized antibodies. This results in a displacement peak
for the labeled analog, as shown in Figure 1(b), and gives a signal that is proportional to the
analyte's free fraction. The retained analyte and labeled analog can later be removed from the
column by using an elution buffer. The column is then allowed to regenerate and the entire
process is repeated for another sample.
Ultrafast immunoextraction and a displacement assay have recently been used with
chemiluminescence detection for the measurement of free thyroxine in serum [1]. However,
this past work involved the use of a complex postcolumn reaction and required serum blanks
to correct for matrix effects on the chemiluminescence signal [1]. This current study will
examine an alternative approach using near-infrared (NIR) fluorescent cyanine dyes as labels
(see Figure 2). A major advantage of these labels is they do not require any postcolumn reaction
for detection. In addition, these dyes have low background signals for many biological samples
and can provide detection limits in the femtomole range [29]. These dyes have been used in
DNA sequencing, traditional immunoassays and capillary electrophoresis [29,30], but they
have not yet been used in either chromatographic immunoassays or in the measurement of free
drug fractions. Although more traditional fluorescent labels have been employed in some types
of chromatographic-based immunoassays [31-34], these other labels have also not been used
in UFIDA methods or free drug assays.
This current study will explore the combined use of NIR fluorescent dyes and UFIDA for
measuring free phenytoin fractions. One parameter that will be examined in this study is the
development of immunoextraction microcolumns that can bind free phenytoin on the
millisecond time scale. The creation and use of NIR fluorescent labeled analogs of phenytoin
for displacement assays will also be considered. The final UFIDA method will be evaluated
in terms of its accuracy, precision and speed when analyzing both drug-protein mixtures and
serum samples. The advantages and limitations of this method will then be considered, as well
as its possible extension to other analytes.
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EXPERIMENTAL SECTION
Reagents
The phenytoin (99% pure), mouse IgG, human plasma (lyophilized, pooled) and HSA (Cohn
fraction V, 99% fatty acid free) were from Sigma-Aldrich (St. Louis, MO). The IRDye 800
CW dye (N-hydroxysuccinimide, or NHS ester) was donated by LI-COR Biosciences (Lincoln,
NE). The monoclonal anti-phenytoin antibodies (clone P0825.1, purified from ascites fluid;
stored in pH 7.2 phosphate buffered saline plus 0.05% sodium azide) were from Accurate
Chemical (Westbury, NY). Nucleosil Si-300 (7 μm particle size, 300 Å pore size) was
purchased from P.J. Cobert (St. Louis, MO). Reagents for the bicinchoninic acid (BCA) protein
assay were from Pierce (Rockford, IL). The phenytoin calibration standards, free phenytoin
calibrators and control serum samples (pooled serum containing known amounts of phenytoin)
were from Abbott Laboratories (Chicago, IL). Other chemicals were reagent grade or better.
All aqueous solutions were prepared using deionized water from a Nanopure water system
(Barnstead, Dubuque, IA).
Apparatus
Mass spectra of phenytoin and its conjugates were obtained using electron ionization mass
spectrometry (EI-MS) performed on a VG AutoSpec mass spectrometer from Fisons (now
Waters/Micromass) (Milford, MA). 1H NMR spectra were acquired for phenytoin and its
conjugates on a Bruker DRX Avance 500 MHz spectrometer (Billerica, MA) using samples
dissolved in deuterated dimethylsulfoxide (DMSO). Ultrafiltration was performed using
Centrifree Micropartition Devices (MW cutoff, 30 kDa; sample capacity, 0.15−1.0 ml) from
Amicon (Danvers, MA), along with a fixed rotor basket centrifuge from Dynac (Parsippany,
NJ). The temperature during the ultrafiltration experiments was controlled by placing the
centrifuge in a Precision P3 incubation cabinet from Expotech (Houston, TX). Samples for the
BCA protein assay were analyzed using a Shimadzu UV160U absorbance spectrophotometer
(Kyoto, Japan). The fluorescence properties of the labeled phenytoin and serum samples were
examined using a QuantaMaster spectrofluorometer from Photon Technology International
(Rockwood, TN), using an excitation wavelength of 770 nm and an emission wavelength range
of 780−900 nm.
The HPLC system used to analyze free phenytoin fractions after ultrafiltration consisted of a
Jasco PU980 pump (Easton, MD), an Alltech water jacket, and a LDC Analytical 3100 UV
detector (Riviera Beach, FL), along with a 2.1 mm I.D. × 4.5 cm HSA column (prepared as
described previously) [8,35]. Samples were injected onto this system using a 20 μL sample
loop and a Thermoseparations AS3000 autosampler (Schaumberg, IL). The same
chromatographic system was used to determine the extraction efficiency of the anti-phenytoin
immunoextraction microcolumns, with these columns or their controls being used in place of
the HSA column. The immunoextraction microcolumns were packed according to a previous
method [36,37].
The chromatographic system used for the UFIDA method was similar to that described in the
previous paragraph but included a second Jasco PU980 pump and a Rheodyne model EV700
six port switching valve (Cotati, CA) for alternating passage of the application and elution
buffers through the anti-phenytoin immunoextraction microcolumn. The labeled phenytoin
was injected onto this system in volumes ranging from 5 to 100 μL, followed by 5 μL injections
of the sample. Detection of the labeled phenytoin was performed using a custom-built HPLC
NIR fluorescence detector from LI-COR. This detector was constructed with a 25 μL flow cell
positioned at the interface of the laser and detector focus, using the same optical system as
described in Ref. [38], with the laser diode source and microscope detector being positioned
90° with respect to the flow cell. The emitted wavelength of the laser diode was 785 nm.
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Excitation wavelengths were selected using a 20 nm bandpass filter centered at 820 nm. The
temperature of the immunoextraction microcolumn or control column was maintained by using
water jackets (Alltech) and a Brinkmann circulating water bath (Westbury, MA). All
chromatographic data were collected using programs written in Labview 5.1 (National
Instruments, Austin, TX). Retention times and areas of the resulting chromatographic peaks
were calculated using PeakFit 4.12 (Systat Software, Richmond, CA).
Preparation of labeled phenytoin
Phenytoin was converted into an amine derivative (i.e., 3-N-amino-5,5-diphenylhydantoin, or
ADPH) by the reaction scheme shown in Figure 2 [39-42]. This involved heating a mixture of
2.50 g phenytoin (0.01 mol) with 3.90 mL hydrazine hydrate (0.08 mol) at 135°C for 5 h; no
other solvent was required for this reaction. ADPH was recrystallized by placing 1 g of the
solid product in approximately 15 mL ethanol. Deionized water was then added and this
mixture was allowed to stand undisturbed at 4°C for two days. The resulting crystals were
filtered and dried at 80°C under vacuum for 8 h. When analyzed by EI-MS, the product of this
reaction gave a molecular ion with a mass-to-charge ratio of 267.1019 (mass accuracy, 4.2
ppm) and fragment ions with masses in agreement with those previously reported for ADPH
[39]. A 1H NMR spectrum for this substance also agreed with that expected for ADPH. Some
byproduct (i.e., 5,5-diphenyl-1,2,4-triazine-3,6-dione) was also noted in this preparation,
which was estimated to make up approximately 40−50% of the final product.
ADPH was conjugated to NHS-activated IRDye 800 CW dye by using an approach similar to
that shown in Figure 2 [43]. This involved dissolving 9 μmol of NHS-activated IRDye 800
CW dye in 0.5 mL DMSO, followed by the slow addition of 20 μmol ADPH in 0.5 mL DMSO
and 1 mL of pH 8.0, 0.10 M potassium phosphate buffer. The resulting mixture was slowly
stirred with a magnetic stir bar for 4 h in an ice water bath. This mixture was then dried to
remove all solvent, with the remaining residue being dissolved in 10 mL of pH 7.4, 0.067 M
potassium phosphate buffer. This product was extracted three times with 10 mL portions of
ethyl acetate to remove any unconjugated reactants. The remaining aqueous fraction was dried
to remove any ethyl acetate; this gave a residue containing the phenytoin-dye conjugate and
unconjugated dye. No further purification of the final labeled-phenytoin dye conjugate (i.e.,
“labeled phenytoin”) was required for this study.
The purity of the labeled phenytoin in the final product was estimated to be 62%. This purity
was sufficient for use in this study, since an excess of labeled phenytoin was used in the
displacement assay. It was found later that the 38% of unconjugated dye in this preparation
did not create any noticeable interference due to background signal or nonspecific binding in
the final UFIDA assay. The purity of this labeled phenytoin was measured by comparing the
NIR fluorescence for the retained peak (i.e., the labeled phenytoin) and non-retained peaks
(containing the unconjugated dye) when a 5 μL sample of this preparation was injected in pH
7.4, 0.067 M potassium phosphate buffer at 0.5 ml/min onto a 2.1 mm I.D. × 4.5 cm
immobilized HSA column, with pH 7.4, 0.067 M potassium phosphate buffer also being used
as the mobile phase. This HSA column was prepared as described earlier [8,35,44,45] and had
a protein content of 28 (± 2 mg) HSA/g silica (± 1 SD). As has been noted for phenytoin [8,
35], this HSA column was found to retain the labeled phenytoin while the free acid form of
the NIR fluorescent dye eluted near the column void volume of this column.
A stock solution was made for the labeled phenytoin in pH 7.4, 0.067 M phosphate buffer. The
concentration of labeled phenytoin in this stock solution was estimated to be 558 (± 20) μM
after a correction was made for unconjugated dye in the final product. This concentration was
determined by HPLC, as described in the previous paragraph, using both this stock solution
and standards containing known concentrations of the NIR fluorescent dye. When not in use,
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this stock solution was stored in the dark in an amber vial at 4°C. This stock solution was used
over the course of approximately four months during this study.
Preparation of immunoextraction microcolumn
Prior to immobilization, the anti-phenytoin antibodies were transferred from their original
solution (pH 7.2 phosphate buffered saline containing 0.05% sodium azide) into pH 6.0, 0.10
M potassium phosphate buffer. This transfer was accomplished by applying a 3.0 mL sample
of these antibodies to a 10 mL Econo-PAC 10DG column (exclusion limit, 6,000 Da) from
BioRad (Hercules, CA) using pH 6.0, 0.10 M potassium phosphate buffer as the mobile phase.
The collected antibodies were stored at 4°C in the same pH 6.0, 0.10 M phosphate buffer.
Prior to its use in immobilization, Nucleosil Si-300 silica was converted into a diol-bonded
form according to a previous method [44]. The final diol coverage of this material was 306 (±
3) μmol/g silica, as determined in triplicate by an iodometric capillary electrophoresis assay
[45]. The anti-phenytoin antibodies in pH 6.0, 0.10 M potassium phosphate buffer were
immobilized onto this diol-bonded silica by the Schiff base method [46]. An inert control
support was prepared in an identical manner but with no antibodies being added during the
immobilization step (note: this type of support was found to be an adequate control for this
work because of the specificity of the anti-phenytoin antibodies and relatively low nonspecific
binding of the analytes or labeled analogs to the control support; however, a control support
containing immobilized nonspecific antibodies could also be used). After immobilization, the
anti-phenytoin support was washed three times with pH 7.4, 0.067 M potassium phosphate
buffer and stored at 4°C until use. A portion of this support was washed several times with
deionized water, dried, and analyzed in triplicate by a BCA protein assay [47]. This assay gave
a protein coverage of 29 (± 7) mg antibodies/g silica when using mouse IgG as the standard
and the control support as the blank.
The anti-phenytoin support was used to prepare immunoextraction microcolumns [2,37] which
had an inner diameter of 2.1 mm and a total length of 0.5 cm. The central layer of these columns
was approximately 1 mm thick (940 μm) and contained the anti-phenytoin support, while the
remainder of the columns contained the inert control support. These columns were prepared
by making fifteen 50 μL injections at 3 mL/min of a 4.2 mg/mL slurry of the control support
to one end of the column in the presence of pH 7.4, 0.067 M phosphate buffer. This was
followed by application of the same buffer at 5 ml/min for 5 min to stabilize this layer to a
thickness of approximately 0.20 cm. A small layer of the anti-phenytoin support was next
placed within this column by making fourteen, 50 μL injections of a 2.1 mg/mL slurry of this
material in pH 7.4, 0.067 M phosphate buffer and at 3 mL/min; this layer was also stabilized
by later increasing the flow rate to 5 mL/min for 5 min. The remainder of this column was
filled in the same manner with the inert control support. Each immunoextraction microcolumn
was stored in pH 7.4, 0.067 M phosphate buffer at 4°C when not in use. The typical
backpressure of these columns at 0.5 to 1.6 mL/min was 130 to 420 psi (0.9 to 2.9 MPa) and
increased by only 19% over four months of regular use.
Characterization of immunoextraction microcolumn
The amount of active anti-phenytoin antibodies in the immunoextraction microcolumns was
determined by frontal analysis [47,48]. This was performed using solutions that contained 2
to 40 μM phenytoin in pH 7.4, 0.067 M phosphate buffer and that were applied at 1.2 mL/min.
The breakthrough curves for phenytoin were monitored at 205 nm, with all runs being
conducted in triplicate at 37°C. Elution of the retained phenytoin was accomplished by
applying pH 2.5, 0.067 M phosphate buffer to the immunoextraction microcolumns. Sample
application and column regeneration were performed by using pH 7.4, 0.067 M phosphate
buffer as the mobile phase. Corrections for the system void time and non-specific binding of
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phenytoin to the column were made by conducting identical experiments using a column with
the same dimensions as the immunoextraction microcolumn but containing only control
support. The extent of phenytoin binding to this control support was less than 8% of the total
binding measured for the immunoextraction microcolumn [8,35].
The extraction efficiency of the immunoextraction microcolumn was determined by making
20 μL injections of a 6 μM phenytoin standard at 37°C in pH 7.4, 0.067 M phosphate buffer;
these injections were made onto both a column containing only the control support and onto
the immunoextraction microcolumn. The amount of non-retained phenytoin was measured on
each column at 205 nm and at flow rates ranging from 0.6 to 1.6 mL/min. Similar experiments
were conducted when no column was present. The difference between the total peak areas
measured with the control column and with no column present was less than 3%.
Ultrafiltration of phenytoin samples
Ultrafiltration was used as a reference method for validating the free fraction measurements
made for phenytoin in this study [4,19,21,49]. This was performed on control serum samples
containing known concentrations of phenytoin and on various HSA/phenytoin mixtures in pH
7.4, 0.067 M potassium phosphate buffer. Each of these samples was centrifuged in the
presence of an ultrafiltration membrane at 37°C for 45 min at 1,500 × g. After centrifugation,
approximately 0.5 mL of the filtrate was collected and stored at 4°C until further use. The
concentration of free phenytoin in the filtrate was measured by using HPLC along with the
same HSA column described earlier for examining the purity of the labeled phenytoin. Samples
containing 20 μL of the filtrate were injected onto this column in triplicate at 0.5 mL/min and
at room temperature. The elution of phenytoin was monitored at 205 nm and gave a retention
factor of 2.3 on this column. No peaks from other sample components were noted in the vicinity
of the retention time for phenytoin. A linear response was obtained on this column for phenytoin
standards containing 2 to 15 μM phenytoin in pH 7.4, 0.067 M phosphate buffer (correlation
coefficient, 0.9998 for n = 5).
Non-specific binding by phenytoin in the ultrafiltration device was measured by using a series
of standards that contained phenytoin in pH 7.4, 0.067 M phosphate buffer. The amount of
phenytoin in the recovered filtrate was then determined by HPLC, as described previously.
These experiments indicated that phenytoin had 7.6 (± 0.1)% nonspecific binding to
ultrafiltration membrane, in agreement with earlier studies [19]. All phenytoin results obtained
by ultrafiltration were corrected for nonspecific binding based on this value.
Ultrafast immunoextraction/displacement assay
The labeled phenytoin and immunoextraction microcolumn developed in this work were used
in an UFIDA method according to the scheme given earlier in Figure 1(a). At the beginning
of this assay, 20 μL of a 55.8 μM sample of the labeled phenytoin was applied to the
immunoextraction microcolumn at 0.8 mL/min using pH 7.4, 0.067 M potassium phosphate
buffer as the mobile phase. Once a baseline had been established, the flow rate was increased
to 1.2 mL/min. A 5 μL sample containing a phenytoin/HSA mixture or phenytoin in human
serum was injected at 6 min after application of the labeled phenytoin. Once the resulting
displacement peak had eluted, the retained phenytoin and any remaining labeled phenytoin
were removed from the column by applying a pH 2.5, 0.067 M phosphate solution as the elution
buffer at 1.2 mL/min for 5 min. The column was then regenerated by applying pH 7.4, 0.067
M phosphate buffer at 0.8 mL/min for 5 min prior to the next application of the labeled
phenytoin. All experiments measuring free phenytoin concentrations on this system were
performed in triplicate at 37°C. Further details on how the conditions for this final method
were selected can be found later in this study.
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RESULTS AND DISCUSSION
Selection of conditions for ultrafast immunoextraction
An underlying requirement for free drug measurements by ultrafast immunoextraction is that
this method must be able to extract a representative portion of a drug's free fraction while
avoiding any appreciable release of the same drug from its bound form in the sample. The
timescale needed for this can be estimated by using the dissociation rate constant of a drug
from its carrier agents in a sample along with the extent of this binding in typical samples [1,
2,36]. Several previous reports have examined the binding of phenytoin to HSA [8,35]. Two
specific regions on HSA that are involved in this binding are the indole-benzodiazepine site
(Sudlow site II) and the digitoxin site of HSA. These sites have been reported to have
association equilibrium constants for phenytoin of 1.04 × 104 and 6.5 × 103 M−1, respectively,
at pH 7.4 and 37°C. It has also been found that phenytoin has allosteric plus possible direct
interactions with the warfarin-azapropazone site (Sudlow site I) and tamoxifen site of HSA
[8,35].
Through previous kinetic measurements using HSA columns, the overall dissociation rate
constant for phenytoin from these binding sites of HSA has been estimated to be 10.8 (± 0.05)
s−1 at pH 7.4 and 37°C [50]. Based on this result and previous work performed in the ultrafast
immunoextraction of warfarin and thyroxine [1,2], it was originally estimated that the analysis
of free phenytoin by UFIDA would require a sample residence time in an immunoextraction
microcolumn of less than 200 ms. To obtain these conditions, a sandwich microcolumn was
used that contained a 2.1 mm I.D. × 940 μm thick layer of an anti-phenytoin support. This gave
an expected residence time for samples in the immunoextraction layer of roughly 100 ms at a
flow rate of 1.2 mL/min.
The binding capacity of the immunoextraction microcolumn was estimated by frontal analysis
to be 67 (± 3) pmol phenytoin at pH 7.4 and 37°C. It was further found from protein assays
that this column contained approximately 290 (± 90) pmol antibodies. This gave an effective
concentration of active antibody binding sites in the immunoextraction layer of 3.4 (± 0.2)
μM and a relative activity of the antibodies for phenytoin of 12 (± 3)% (assuming there were
two accessible binding sites per antibody). Although this relative activity was low, the total
column binding capacity was sufficient for this work since it was roughly two times higher
than the amount of free phenytoin expected at the high end of this drug's therapeutic range in
a 5 μL sample (i.e., based on a 90% bound fraction and a total phenytoin concentration of 80
μM). If desired, this relative activity and binding capacity could be improved by employing
more site-selective techniques for antibody immobilization; examples include the use of
hydrazide-activated supports plus antibodies that have been oxidized in their carbohydrate
regions, or the use of biotin tags in these same regions along with avidin or avidin-containing
supports [51-53].
The association equilibrium constant for phenytoin with the immobilized anti-phenytoin
antibodies was determined by frontal analysis to be 5.4 (± 0.3) × 108 M−1 at pH 7.4 and 37°C
(note: no significant change in this value was noted at lower flow rates). Although this result
represents reasonably strong binding, this association equilibrium constant is approximately
20-fold lower than a solution-phase equilibrium constant of 1 × 1010 M−1 that was provided
by the manufacturer of these antibodies. This difference is not surprising because immobilized
antibodies can often have lower binding constants than their soluble forms [54,55]. Using this
equilibrium constant and the binding capacity of the immunoextraction microcolumn, the
retention factor for phenytoin on this column at pH 7.4 and 37°C was estimated to be 348 (±
26). This value was calculated by using the relationship k = KA mL/VM, where KA is the
association equilibrium constant for phenytoin with the antibodies, mL is the moles of active
antibodies in the column, VM is the void volume of the immunoextraction layer, and (mL/
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VM) is the effective concentration of active antibodies in this layer [48]. Further examination
of the frontal results, as described in [28], gave a measured association rate constant (ka) for
phenytoin with the immobilized anti-phenytoin antibodies of 2.4 (± 0.4) × 106 M−1 s−1 at pH
7.4 and 37°C. From the relationship KA = ka/kd, the dissociation rate constant (kd) for phenytoin
from the immobilized antibodies was also determined, giving a value of 4.4 (± 0.8) × 10−3
s−1. All of these results indicated that any phenytoin extracted by the immobilized antibodies
would bind tightly to this column and only slowly dissociate from these antibodies in the
presence of a pH 7.4 buffer.
The ability of this microcolumn to extract phenytoin was measured by comparing injections
of phenytoin standards made onto this column versus injections made onto an inert control
column. Table 1 summarizes the results that were obtained. The concentration and quantity of
phenytoin that was injected (20 μL of a 6 μM solution, or 120 pmol phenytoin) corresponded
to the free amount of this drug that would be expected in serum at typical therapeutic levels.
It was found that 95% or more of the phenytoin was extracted when using residence times of
100 ms or greater in the immunoextraction layer, with 98% being extracted at residence times
of 150 ms or greater. These results are in agreement with previous observations made for the
ultrafast immunoextraction of thyroxine and warfarin [1,2].
The immunoextraction microcolumn was also used in studies examining the effect of flow rate
and sample residence on the apparent free fraction that was obtained for phenytoin in a
displacement assay. It was found that a flow rate of 1.2 mL/min or greater (i.e., a sample
residence time in the immunoextraction layer of 103 ms or less) gave a consistent measured
free phenytoin fraction of 15.8% for the test mixture in Table 1. However, slower flow rates
and longer sample residence times resulted in a greater apparent free fraction (1.9% higher at
0.8 mL/min and 5.7% higher at 0.6 mL/min). As indicated in previous simulations performed
for warfarin and thyroxine [1,2], this increase in the apparent free fraction is believed to reflect
dissociation of the analyte from proteins or other binding agents in the sample. Thus, as a
compromise between extraction efficiency and accuracy, an injection flow rate of 1.2 mL/min
(i.e., a sample residence time of roughly 100 ms in the immunoextraction layer) was used in
all later experiments for free phenytoin measurements.
Behavior of NIR fluorescent label under assay conditions
The next item considered was the signal intensity and behavior of the labeled phenytoin under
the conditions to be used for ultrafast immunoextraction. It was found in pH 7.4, 0.067 M
phosphate buffer that the NIR fluorescence of the labeled conjugate gave a linear response over
a broad range of concentrations. This linear range extended from approximately 1.7 fmol to
2.1 pmol (i.e., 0.33 to 412 nM for a 5 μL injection, with a lower limit of detection of 1.4 nM
at a signal-to-noise ratio of three). Although this amount is less than the free phenytoin levels
in 5 μL of serum (i.e., 20 to 40 pmol or 4 to 8 μM), this UFIDA format only requires that a
small, representative amount of the labeled phenytoin be displaced by an injected analyte. Thus,
as will be seen later, the response for the NIR fluorescent label was more than adequate for
analyzing the displacement peaks that were created during the detection of free phenytoin
fractions in such samples.
Another item examined was the effect of biological samples on the fluorescence of the labeled
phenytoin. This was of interest since it has been noted in previous work with chemiluminescent
labels that up to a 30% change in signal can be seen for a labeled analyte in the presence of
serum versus buffer [1]. To study this effect, the emission spectrum of the labeled phenytoin
was obtained in the presence and absence of human plasma (i.e., serum plus clotting factors),
as shown in Figure 3(a). It was found that there was no appreciable reduction in signal intensity
(i.e., less than 3% change) between a buffered standard and plasma containing labeled
phenytoin. Similar results were obtained when comparing plasma and buffered solutions
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containing 0.33 to 412 nM labeled phenytoin, which gave less than a 17% difference in signal
at all concentrations examined. The similarity of the plasma and buffer results indicated that
there was either only a small amount of binding between the labeled phenytoin and HSA in
plasma or that this binding did not have any appreciable affect on the NIR fluorescence of the
dye in this conjugate.
The actual extent of interferences from the sample matrix would be expected to be even smaller
than 3 to 17% when the labeled phenytoin is used in a displacement assay, since the peak for
the displaced conjugate elutes slightly after the non-retained fraction of the sample. This is
demonstrated in Figure 3(b), where even the highest concentration standards gave displacement
peaks with a mean elution time that occurred 1 min after the non-retained components of a
serum sample (as represented by HSA). The overlap of the sample and displacement peaks
was estimated to be less than 5% for this assay, which would further reduce any effects of the
sample matrix on the fluorescent signal of the NIR dye used in the labeled phenytoin.
The emission spectrum for a sample of human plasma with no NIR dye added was acquired to
see what type of background signal could be expected from such a sample. This spectrum is
also shown in Figure 3(a) and gave no detectable signal at the emission wavelengths that were
monitored. From this result, as well as the difference in sample and displacement peak elution
times noted in Figure 3(b), it was concluded that no significant background signal should have
been present under the conditions used in this study for detection of the labeled phenytoin in
the displacement peaks.
Optimization of UFIDA method
After the initial conditions for ultrafast immunoextraction and detection of the labeled
phenytoin had been selected, these components were combined and optimized for use in an
UFIDA assay for measuring free phenytoin fractions. One item considered was the effect of
varying the amount of labeled phenytoin that was applied to the system for analyte detection.
This item was studied by applying 5 to 100 μL of a 0.558 to 55.8 μM solution of the labeled
phenytoin (i.e., 2.8 pmol to 5.6 nmol) at 0.8 ml/min to the immunoextraction microcolumn
prior to the injection of a 5 μL sample of 35 μM phenytoin (i.e., a typical therapeutic
concentration expected for free phenytoin in serum). The amount of labeled phenytoin used
under these conditions ranged from 0.04- to 84-times the binding capacity of the
immunoextraction microcolumn. The area of the displaced peak gave less than a 6% change
when the amount of labeled phenytoin was at least 110 pmol (e.g., a 20 μL injection of 5.58
μM labeled phenytoin), or conditions in which the amount of the labeled phenytoin was present
in more than a 1.6-fold excess versus the column binding capacity.
The only change noted when using larger amounts of labeled phenytoin was a slight increase
in the time it took to wash the excess, non-retained labeled conjugate from the column. When
using small amounts of this conjugate, it took approximately 3 min to remove 99.9% of the
non-retained labeled phenytoin from the column. However, it took around 5.5 min to wash off
the excess conjugate when using the highest amounts of labeled phenytoin that were examined
in this work. Based on these results, a 20 μL injection of a 5.58 μM preparation of the labeled
phenytoin (i.e., 110 pmol) was used along with a wash time of 3 min in the final UFIDA method
as a compromise between assay speed and response.
Another item considered in developing the UFIDA method was the effect of varying the time
between injection of the labeled phenytoin and the injection of a sample. This was examined
to see if overlap of the sample peak with the remaining non-retained labeled phenytoin (at small
injection times) or loss of the retained labeled phenytoin (at long injection times) gave a
significant change in response for the displacement peak. The results of these studies are shown
in Figure 4(a). Using the displacement peak obtained with sample injection at 2 min as the
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reference, the changes in area noted for displacement peaks measured after sample injections
at 4, 6 or 12 min were 1.7, 1.9, and 4.8% respectively. It was concluded from these data that
sample injection should be performed in 2 to 6 min after application of the labeled phenytoin
to give less than 2% variation in the displacement peak's size. These conditions minimized loss
of the retained labeled phenytoin while also allowing sufficient time for excess labeled
conjugate (and any associated contaminants) to be washed from the column.
The next study considered the use of sequential sample injections during the UFIDA method.
This was done to determine if it was possible to perform more than one analysis per column
loading of the labeled phenytoin. As shown in Figure 4(b), the use of two sequential sample
injections gave less than a 5% change in displacement peak area and less than a 3% change in
peak height. The intensity of the displacement peaks then began to decrease with further sample
injections, giving signals that were 36 and 93% lower (versus the first sample) for the third
and fourth injections. In the remainder of this study only one sample injection was performed
after each application of the labeled phenytoin. However, the findings in Figure 4(b) indicate
that multiple injections could be used in such an assay to further increase sample throughput
in the UFIDA method.
Elution of the retained phenytoin and labeled phenytoin in the UFIDA method was
accomplished by using a pH 2.5, 0.067 M phosphate buffer applied at 1.2 mL/min for 5 min.
Regeneration of the immunoextraction microcolumn was conducted by applying pH 7.4, 0.067
M phosphate buffer for at least 5 min prior to a new injection of labeled phenytoin. The UFIDA
method was found to be quite stable under these conditions, allowing a reproducible response
to be obtained on a single column over at least 250 injections and four months of regular use.
Validation of UFIDA method
The final conditions used in the UFIDA assay for free phenytoin measurements are summarized
in the Experimental Section. An example of a typical run obtained under such conditions is
given in Figure 1(b). The displacement peak for this assay occurred within 2−3 min of sample
injection, and the total assay time (i.e., one injection, elution and regeneration cycle) was 20
min. However, it was found that the total time to detect and analyze free phenytoin fractions
could be reduced to less than 10 min per sample by using multiple sample injections after each
application of the labeled phenytoin (see previous section).
A typical calibration curve obtained for the UFIDA method is shown in Figure 5. The lower
limit of detection for this method was 570 pM phenytoin (S/N = 3) for a 5 μL sample (i.e., 2.9
fmol). The linear range (i.e., the range of analyte concentrations giving a response within 10%
of the best-fit line) extended from the lower limit of detection up to approximately 10 μM
phenytoin (approximately 50 pmol). This linear response covered the entire range of free
phenytoin concentrations that would be expected at normal therapeutic levels of this drug. The
calibration curve for this assay leveled off as phenytoin concentrations above 10 μM were
injected. This behavior is probably due to saturation of the immunoextraction microcolumn,
since these high sample concentrations gave rise to amounts of phenytoin that approached or
exceeded the binding capacity of this system (i.e., 50 pmol phenytoin in 5 μL of a 10 μM sample
versus a 67 pmol binding capacity for the column).
The precision of this assay was determined by making replicate injections of standards,
phenytoin/HSA mixtures and spiked control serum samples. A relative standard deviation of
±0.5% or less was seen for standards containing free phenytoin concentrations of 1.24 nM to
2.02 μM. As will be shown later, the precision was ! 2 to 5% for serum and HSA samples that
contained phenytoin at typical therapeutic concentrations.
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The accuracy of the UFIDA assay was first assessed by comparing it to ultrafiltration in the
analysis of phenytoin/HSA mixtures that had been prepared in pH 7.4, 0.067 M potassium
phosphate buffer (see Table 2). The sample concentrations used in this study were chosen to
match the levels of HSA and phenytoin that would be expected in serum samples containing
typical therapeutic concentrations of phenytoin. These samples gave average free phenytoin
fractions of 15.9, 13.7 and 12.0% at HSA concentrations of 550, 650 and 750 μM, respectively
(i.e., results similar to literature values reported for free phenytoin fractions in serum) [11,
14]. All of the twenty-five phenytoin/HSA samples that were examined gave statistically
identical results at the 95% confidence level for UFIDA versus ultrafiltration. In addition, all
of the UFIDA and ultrafiltration results overlapped within 1 SD of their values and had
differences in these values of only 1.6 to 5.4% (average, 2.9%). Although there was a small
apparent bias in the ultrafiltration results compared to UFIDA, the size of this bias was strongly
linked with experimental uncertainly in the nonspecific binding measured for the ultrafiltration
membranes.
Another comparison was made between UFIDA and ultrafiltration in terms of their ability to
determine free phenytoin concentrations in human serum. This was conducted with standards
and samples used in a commercial immunoassay kit for free phenytoin [12,15,21]. The four
standards supplied with this kit (total phenytoin concentration, 1.98 to 12 μM in phosphate
buffer) gave a linear response for the UFIDA method, with a best fit line of y = 4.85 (± 0.04)
× + 2.9 (± 3.0) and a correlation coefficient of 0.9932 (n = 4). The results for control serum
samples are shown in Table 3. Comparison of the UFIDA and ultrafiltration results for these
samples again resulted in statistically identical values for the measured free fractions of
phenytoin. When using ultrafiltration, control sera containing 10 to 40 μM concentrations of
total phenytoin gave free phenytoin concentrations of 1.32 to 6.11 μM (or 13.4 to 15.4% free
fractions), while analysis of the same samples using UFIDA gave free phenytoin concentrations
of 1.27 to 5.99 μM (or free fractions of 12.2 to 15.1%). The difference between the results of
these two assays was less than 2 to 5%, with all differences being within 1 SD of the
measurements.
Comparison of UFIDA and ultrafiltration
Although UFIDA and ultrafiltration gave comparable results for the samples in Tables 2 and
3, they did differ in terms of their precision and speed. For instance, the relative precision of
the UFIDA results in Table 2 was 2.4 to 4.8%, while the relative precision of the ultrafiltration
results for the same samples was over two-fold larger, ranging from 8.1 to 9.7%. A similar
trend was noted for the control serum results in Table 3. The worse precision of the
ultrafiltration results is thought to be the combined result of 1) the multiple, manual steps that
are involved in this method and 2) the random experimental variations that were noted in
nonspecific binding of phenytoin to the ultrafiltration membrane. In contrast to this, the UFIDA
method was performed as an automated system that did not require any sample pretreatment
steps, which probably contributed to the better precision of this method versus ultrafiltration.
In terms of speed, UFIDA gave results for each sample within 2−3 min of injection, with a
total run time of 20 min per cycle. For ultrafiltration, the minimum time required for one sample
was approximately 1 h, which included 45 min to perform the ultrafiltration and 15 min to
conduct the HPLC analysis of the filtrate's free phenytoin content. For UFIDA, a total of 15 h
was required for a triplicate analysis of all the samples and standards used to generate the data
in Table 2. Although ultrafiltration has a much higher analysis time per sample, up to 15
samples could be centrifuged simultaneously in this approach, giving it an overall sample
throughput comparable to that of the UFIDA method (i.e., 14 h for analysis of all samples and
standards used in Table 2). However, it should be kept in mind that the throughput of the
UFIDA method could be increased by almost two-fold by using sequential injections of
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samples after each application of the labeled phenytoin, as demonstrated earlier in Figure 4(b).
This throughput could be improved even further through the use of multiple immunoextraction
columns and a multi-port valve for flow-splitting. Thus, UFIDA has the capability of not only
providing a faster analysis per sample than ultrafiltration but can also provide higher sample
throughput in some applications.
CONCLUSIONS
This study examined the development and validation of NIR fluorescent labels and an ultrafast
immunoextraction/displacement assay for free fraction measurements of the drug phenytoin.
The final system used an immunoextraction microcolumn that allowed for the extraction and
analysis of free phenytoin when using a sample residence time as low as 100 ms. Phenytoin
that had been labeled with a NIR fluorescent dye was then combined with this microcolumn
to provide detection limits for phenytoin down to the picomolar range without any observable
background signals or matrix effects from serum samples.
The UFIDA method developed in this study gave good correlation versus ultrafiltration for the
measurement of free phenytoin fractions in serum and phenytoin/HSA samples. This new
method allowed free phenytoin fractions to be measured within 2−3 min of sample injection,
while giving a precision and analysis time per sample that was much better than that obtained
for ultrafiltration. This method is also much faster than the technique of equilibrium dialysis
and, unlike methods based on capillary electrophoresis and RAM columns, can easily be used
for free analyte measurements in real clinical samples. Although this method does require
appropriate antibodies and labeled analogs for the drug or analyte of interest, this is not a major
limitation since these reagents can be obtained or modified from those used for the same
analytes in other types of immunoassays. These properties should make the UFIDA method
useful in a variety of areas, including therapeutic drug monitoring, pharmacological studies,
and measurements of drug-protein binding [1,2,5,6,13-15,20,21,27,56,57].
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Figure 1.
(a) General scheme for an ultrafast immunoextraction/displacement assay (UFIDA) and (b) a
typical chromatogram for such an assay. The example in (b) is based on the phenytoin system
described in the Experimental Section. In (b) the excess labeled phenytoin was injected at 0
min and the sample containing the unlabeled phenytoin was injected at 6 min. Symbols: ,
labeled analog of analyte; , unlabeled analyte from sample; , binding agent in a sample for
the analyte; , immobilized antibody.
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Figure 2.
Scheme for the synthesis of a phenytoin conjugate containing a label based on a near-IR
fluorescent dye. The first reaction (a) shows the preparation of 3-N-amino-5,5-
diphenylhydantoin (ADPH), while the second reaction (b) shows how ADPH was used to
prepare the final labeled phenytoin. The dye shown in this example is NHS-activated IRDye
700DX from LI-COR Biosciences, which is similar to the proprietary dye used in this current
study [29].
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Figure 3.
(a) Emission spectrum for human plasma and labeled phenytoin in the presence of plasma or
pH 7.4, 0.067 M phosphate buffer, and (b) chromatograms for a UFIDA method performed
for samples containing free phenytoin concentration of 4 to 8 μM injected at 6 min after the
application of labeled phenytoin. A chromatogram is also shown (b) that was obtained under
the same conditions for a 5 μL, 550 μM sample of HSA (representing the main protein of serum
or plasma and a non-retained component in the UFIDA method), as monitored using
absorbance detection at 205 nm. The emission spectra in (a) were obtained using a 100 μM
solution of labeled phenytoin in plasma or buffer at an excitation wavelength of 770 nm.
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Figure 4.
Effect of (a) injection time on the application of phenytoin samples to the UFIDA system and
(b) the use of sequential sample injections in this assay. The experiments with the injection
time were performed using a 5 μL, 4 μM phenytoin sample. The sequential injection studies
were performed using a sample containing 30 μM phenytoin and 550 μM HSA. In both (a) and
(b), the column was loaded with 20 μL of a 5.58 μM solution of labeled phenytoin at 0.8 mL/
min, with the flow rate being changed to 1.2 mL/min after 1.5 min into each run and before
sample injection.
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Figure 5.
(a) Calibration curve based on displacement peak area for phenytoin in the UFIDA method.
The experimental conditions are given in the text. The best-fit line over the linear range in (a)
was y = 5.58 (± 0.02) × + 0.010 (± 0.106), with a correlation coefficient of 0.9999 (n = 10).
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Table 1
Ultrafast immunoextraction of phenytoin at various flow rates in a sample containing a fixed total amount of phenytoin
and HSAa
Flow rate (mL/min) Residence time in antibody layer of
immunoextraction microcolumn
(ms)
Extraction efficiency (%) Measured free fraction
phenytoin (%)
0.6 207 100 (± 10) 16.7 (± 0.6)
0.8 155 98 (± 2) 16.1 (± 0.5)
1.2 103 95 (± 3) 15.8 (± 0.5)
1.4 89 92 (± 3) 15.8 (± 0.4)
1.6 78 87 (± 5) 15.8 (± 0.2)
a
These values were determined using sample that contained 550 μM HSA and 35.0 μM phenytoin. The numbers in parentheses represent a range of ±1
SD.
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Table 2
Determination of free phenytoin fractions in phenytoin/HSA mixtures by ultrafiltration or a UFIDA methoda
Measured free phenytoin conc. (μM)
Total conc. HSA (μM) Total conc. phenytoin (μM) Ultrafiltration UFIDA
550 30 4.9 (± 0.4) 4.7 (± 0.2)
550 35 5.7 (± 0.5) 5.5 (± 0.2)
550 40 6.6 (± 0.6) 6.4 (± 0.2)
550 45 7.5 (± 0.7) 7.2 (± 0.2)
550 50 8.3 (± 0.7) 8.1 (± 0.2)
650 30 4.2 (± 0.4) 4.1 (± 0.1)
650 35 4.9 (± 0.4) 4.8 (± 0.1)
650 40 5.6 (± 0.5) 5.5 (± 0.1)
650 45 6.4 (± 0.6) 6.2 (± 0.2)
650 50 7.1 (± 0.6) 6.9 (± 0.2)
750 30 3.7 (± 0.3) 3.5 (± 0.1)
750 35 4.3 (± 0.4) 4.2 (± 0.2)
750 40 4.9 (± 0.4) 4.8 (± 0.2)
750 45 5.6 (± 0.5) 5.4 (± 0.2)
750 50 6.2 (± 0.6) 6.1 (± 0.2)
a
All measurements were performed at 37°C in pH 7.4, 0.067 M phosphate buffer. The values for ultrafiltration have been corrected for nonspecific binding
to the membrane. The numbers in parentheses represent a range of ± 1 SD.
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Table 3
Determination of free phenytoin fractions in serum samples by ultrafiltration or a UFIDA methoda
Measured free phenytoin conc. (μM)
Total conc. phenytoin (μM) Ultrafiltration UFIDA
10 1.32 (± 0.34) 1.27 (± 0.05)
20 2.81 (± 0.42) 2.70 (± 0.12)
40 6.11 (± 0.44) 5.99 (± 0.14)
a
All measurements were performed in pH 7.4, 0.067 M potassium phosphate buffer and 37°C. The values for ultrafiltration have been corrected for
nonspecific binding to the membrane. The values in parentheses represent! 1 SD.
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